Tomuzotuximab - Glycotope
Alternative Names: CetuGEX; Cetuximab biobetter - Glycotope; GT-MAB 5.2-GEXLatest Information Update: 28 Jul 2023
Price :
$50 *
At a glance
- Originator GLYCOTOPE
- Developer Glycotope
- Class Antineoplastics; Biobetters; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Head and neck cancer
- Phase I/II Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Renal cancer
- No development reported Solid tumours
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Germany (IV)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Italy (IV)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Spain (IV)